OtherBasic Science (Animal or Phantoms)
Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma
Zhen Yang, Feng Li, Yuqian Huang, Na Yin, Junjun Chu, Ying Ma, Roderic I Pettigrew, Dale Hamilton, Diego Martin and Zheng Li
Journal of Nuclear Medicine February 2022, jnumed.121.263151; DOI: https://doi.org/10.2967/jnumed.121.263151
Zhen Yang
1 Houston Methodist Academic Institute, United States;
Feng Li
1 Houston Methodist Academic Institute, United States;
Yuqian Huang
1 Houston Methodist Academic Institute, United States;
Na Yin
2 Baylor College of Medicine;
Junjun Chu
3 University of Southern California;
Ying Ma
4 National Institutes of Health;
Roderic I Pettigrew
5 Engineering Medicine, Texas A&M University
Dale Hamilton
1 Houston Methodist Academic Institute, United States;
Diego Martin
1 Houston Methodist Academic Institute, United States;
Zheng Li
1 Houston Methodist Academic Institute, United States;

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma
Zhen Yang, Feng Li, Yuqian Huang, Na Yin, Junjun Chu, Ying Ma, Roderic I Pettigrew, Dale Hamilton, Diego Martin, Zheng Li
Journal of Nuclear Medicine Feb 2022, jnumed.121.263151; DOI: 10.2967/jnumed.121.263151
Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma
Zhen Yang, Feng Li, Yuqian Huang, Na Yin, Junjun Chu, Ying Ma, Roderic I Pettigrew, Dale Hamilton, Diego Martin, Zheng Li
Journal of Nuclear Medicine Feb 2022, jnumed.121.263151; DOI: 10.2967/jnumed.121.263151
Jump to section
Related Articles
Cited By...
- No citing articles found.